an elevation of IL-8, followed by IL-6, IL-12 and IL-10. Blood analysis proved no significant findings, though cases of neutrophilia and leukopenia were detected. Conclusions: Limited resources, restricted participation from all the possible H1N1VI patients, thus biasing results due to small sample size; however, the obtained data is consistent with existing reports, nevertheless the information is not enough to establish standardized recommendations. Further collaboration among centers, is needed to identify features that can prompt H1N1VI early identification and prevention in pediatric population. SII = Stational Influenza infection; LS = lymphocyte subpoulations; CBC = Complete blood count, BCH (blood chemistry) = Includes levels of glucose, urea, creatinine, ALT, AST, CPK CPK-MB, amylase and lipase. Background: Computed tomography (CT), a standard diagnostic technique used to evaluate the extent of the sinus disease, fails to show bone involvement in patients with sinusitis. Bone scintigraphy is the gold standard procedure for detecting the bone involvement. Osteitis may be one of the reasons for discrepancies between extent of the disease as evaluated by CT and symptom scores. The aim of the study was to determine whether or not nuclear scintigraphy is useful in the diagnosis and management of acute, complicated acute and chronic sinusitis. Methods: Forty patients with sinusitis were involved (9 acute, 4 complicated acute, 27 chronic sinusitis). 20 of the chronic sinusitis patients were with nasal polyps. All patients were evaluated with CT and SPECT (Single-photon emission tomography). 99Technetium-methylenediphosphate (99Tc-MDP) was administered for scintigraphic examination of the skull. Abnormal patterns of increased radionuclide uptake were identified and subjectively described. The mucosal involvement of sinusitis graded on Lund-Mackay Scale (LMS) was compared to degree of bone involvement evaluated by SPECT. Results: While, SPECT uptakes were negative (mean uptake index is less than about 2.5) in acute sinusitis, it's highly positive (mean uptake index is more than about 4) in complicated acute sinusitis. In group of chronic sinusitis, a positive correlation between the SPECT uptakes and LMS grade was found (P , 0.05). Conclusions: In our view, the bone involvement as evaluated by SPECT correlates with the stage of chronic sinusitis. Poorer subjective response was observed in patients with positive SPECT. The clinical value of scintigraphy, is limited to special indications. Background: Several ultramicroscopic studies have confirmed the presence of biofilms in ENT diseases, such as chronic rhinosinusitis, nasal polyposis or adenoid hypertrophy. Recently, it has been reported that light microscopy nasal cytology can identify biofilms, which appear as cyan-stained "Infectious Spots." Methods: Subjects suffering from a wide spectrum of nasal disorders, after a detailed clinical history and ENT examination, underwent nasal fibroendoscopy, skin prick test, rhinomanometry and nasal cytology. Results: 1410 subjects were studied. The infectious spot was present in 107 of them (7.6%) patients; this percentage reached 55.4% in 193 patients who had clear cytologic signs of infectious rhinitis. Biofilms were largely more frequent in patients with adenoid hypertrophy (57.4%), followed by nasal polyposis (24%), chronic rhinosinusitis (9.5%) and non-allergic "cellular" rhinitis (7.6%). Nasal cytology was normal in the remaining patients, with no infectous spot detectable. Statistical analysis showed that nasal resistances were significantly higher in presence of biofilms in patients affected by adenoid hypertrophy (P ¼ 0.003), nasal polyposis (P , 0.001), chronic rhinosinusitis (P ¼ 0.018) and septal deviation (P ¼ 0.001).
Allergy & Respiratory Diseases, Universita Degli Studi Di Genova, Genoa, Italy. Background: Several ultramicroscopic studies have confirmed the presence of biofilms in ENT diseases, such as chronic rhinosinusitis, nasal polyposis or adenoid hypertrophy. Recently, it has been reported that light microscopy nasal cytology can identify biofilms, which appear as cyan-stained "Infectious Spots." Methods: Subjects suffering from a wide spectrum of nasal disorders, after a detailed clinical history and ENT examination, underwent nasal fibroendoscopy, skin prick test, rhinomanometry and nasal cytology. Results: 1410 subjects were studied. The infectious spot was present in 107 of them (7.6%) patients; this percentage reached 55.4% in 193 patients who had clear cytologic signs of infectious rhinitis. Biofilms were largely more frequent in patients with adenoid hypertrophy (57.4%), followed by nasal polyposis (24%), chronic rhinosinusitis (9.5%) and non-allergic "cellular" rhinitis (7.6%). Nasal cytology was normal in the remaining patients, with no infectous spot detectable. Statistical analysis showed that nasal resistances were significantly higher in presence of biofilms in patients affected by adenoid hypertrophy (P ¼ 0.003), nasal polyposis (P , 0.001), chronic rhinosinusitis (P ¼ 0.018) and septal deviation (P ¼ 0.001).
Conclusions: The results demonstrate that biofilms are not present only in infectious rhinopathies, but also in inflammatory and/or immune-mediateddiseases. Biofilms were more frequent in patients with higher degree of nasal obstruction as assessed by nasal endoscopy (grade III and IV adenoids and stage-3 polyposis) and rhinomanometry. Nasal cytology, by allowing the identification of biofilms represents a useful diagnostic tool with promising research implications. Sunovion Pharmaceuticals, Inc., Marlborough, MA. Background: Ciclesonide hydrofluoroalkane nasal aerosol (CIC-HFA) is currently in development as a potential treatment for allergic rhinitis. The objective of this study was to determine the efficacy and safety of CIC-HFA compared to placebo in subjects with perennial allergic rhinitis (PAR). Methods: Subjects $12 years of age with a $2 year history of PAR were randomized in a placebo-controlled, double-blind, parallel group, multicenter study to CIC-HFA 74 mg (N ¼ 298), CIC-HFA 148 mg (N ¼ 505), or placebo (N ¼ 307) QD AM for 26 weeks. Subject-reported change from baseline in the average of AM and PM reflective total nasal symptom score (rTNSS) and instantaneous total nasal symptom score (iTNSS) averaged over the first 6 weeks of treatment period were key endpoints and were calculated as a sum of the 4 individual nasal symptoms of congestion, runny nose, sneezing, and nasal itching each on a scale of 0 (no signs/symptoms evident) to 3 (severe symptoms). Change from baseline in the individual reflective and instantaneous nasal symptom scores over the first 6 weeks of treatment period were also evaluated. Treatmentemergent adverse events (TEAEs) were assessed throughout the study. Results: CIC-HFA 74 mg and CIC-HFA 148 mg doses demonstrated a statistically significant improvement in rTNSS (LS mean change 0.70 & 0.54 respectively, P # 0.001 for both), iTNSS (LS mean change 0.58 & 0.42 respectively, P # 0.05 for both) and improvements in individual reflective and instantaneous nasal symptoms (P # 0.05 for all, unadjusted for multiplicity) at 6 weeks from baseline. The overall incidence of TEAEs was low and comparable between the CIC treatment groups and placebo. The most frequently reported TEAEs ($2% of subjects in any treatment group) were nausea, headache, sinus headache, cough, upper respiratory tract infection, instillation site discomfort, nasal discomfort, nasopharyngitis, sinusitis, oropharyngeal pain, and epistaxis. Conclusions: In this study, once-daily treatment with CIC-HFA 74mg or CIC-HFA 148mg demonstrated statistically significant improvements in the nasal symptoms of PAR. Both active treatments were well tolerated.
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